Brainstorm Cell Therapeutics Inc Cash Flow Conversion Efficiency
Brainstorm Cell Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Brainstorm Cell Therapeutics Inc (BCLI) has a cash flow conversion efficiency ratio of 0.075x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-895.00K) by net assets ($-11.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Brainstorm Cell Therapeutics Inc (2001–2025)
Cash flow conversion efficiency of Brainstorm Cell Therapeutics Inc from 2001 to 2025. This chart illustrates how Brainstorm Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Brainstorm Cell Therapeutics Inc share price for real-time trading data and today's change.
Brainstorm Cell Therapeutics Inc Cash Flow Conversion Ratio Explained
Brainstorm Cell Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Brainstorm Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brainstorm Cell Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Brainstorm Cell Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sweden BuyersClub AB
ST:BUY
|
0.227x |
|
Trustpilot Group PLC
LSE:TRST
|
-5.609x |
|
Thai Capital Corporation Public Company Limited
BK:TCC
|
0.110x |
|
Tasman Resources Ltd
AU:TAS
|
-0.077x |
|
Gratifii Ltd
AU:GTI
|
0.129x |
|
Caring Brands, Inc. Common Stock
NASDAQ:CABR
|
-0.304x |
|
Stelar Metals Ltd
AU:SLB
|
-0.051x |
|
SunCar Technology Group Inc.
NASDAQ:SDA
|
0.185x |
Annual Cash Flow Conversion Efficiency for Brainstorm Cell Therapeutics Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Brainstorm Cell Therapeutics Inc from 2001 to 2025. Review Brainstorm Cell Therapeutics Inc (BCLI) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.29 Million | $-6.97 Million | 0.678x | -42.13% |
| 2024-12-31 | $-7.76 Million | $-9.09 Million | 1.171x | -72.19% |
| 2023-12-31 | $-4.86 Million | $-20.46 Million | 4.211x | -34.28% |
| 2022-12-31 | $-3.02 Million | $-19.32 Million | 6.408x | +571.89% |
| 2021-12-31 | $19.34 Million | $-26.27 Million | -1.358x | -36.84% |
| 2020-12-31 | $35.46 Million | $-35.19 Million | -0.992x | -207.85% |
| 2019-12-31 | $-12.22 Million | $-11.25 Million | 0.920x | +137.26% |
| 2018-12-31 | $5.02 Million | $-12.39 Million | -2.470x | -514.29% |
| 2017-12-31 | $5.88 Million | $-2.36 Million | -0.402x | +32.04% |
| 2016-12-31 | $9.90 Million | $-5.86 Million | -0.592x | -12.83% |
| 2015-12-31 | $14.13 Million | $-7.41 Million | -0.524x | +22.00% |
| 2014-12-31 | $6.67 Million | $-4.49 Million | -0.672x | +54.58% |
| 2013-12-31 | $2.74 Million | $-4.05 Million | -1.480x | -110.85% |
| 2012-12-31 | $4.15 Million | $-2.92 Million | -0.702x | +53.01% |
| 2011-12-31 | $1.49 Million | $-2.22 Million | -1.494x | -133.14% |
| 2010-12-31 | $-459.00K | $-2.07 Million | 4.508x | +956.02% |
| 2009-12-31 | $-1.74 Million | $-744.00K | 0.427x | -48.90% |
| 2008-12-31 | $-2.08 Million | $-1.73 Million | 0.835x | +14.32% |
| 2007-12-31 | $-2.43 Million | $-1.77 Million | 0.731x | +55.17% |
| 2006-12-31 | $-1.82 Million | $-855.00K | 0.471x | +197.46% |
| 2005-12-31 | $-7.91 Million | $-1.25 Million | 0.158x | +116.45% |
| 2004-12-31 | $704.45K | $-677.84K | -0.962x | -295.97% |
| 2003-12-31 | $-31.44K | $-15.44K | 0.491x | +242.56% |
| 2002-12-31 | $20.36K | $-7.01K | -0.344x | -141.49% |
| 2001-12-31 | $52.16K | $-7.44K | -0.143x | -- |
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modul… Read more